Pathogen safety is a crucial but sometimes overlooked aspect of the development of advanced therapy medicinal products

Industry leaders discuss the past, present and future of advanced therapies in this inspiring video...

Dr Alina Depkat is the customer relations manager at time:matters, a subsidiary of Lufthansa, the largest airline in Europe. She is leading...

We're keeping tabs on the innovators and disruptors for you  

A summary of all of the regenerative medicine CMOs in Japan is presented in this infographic

Without capacity; manufacturing expertise; innovation and partnerships, advanced therapies cannot be commercialised nor delivered to patients ...

One of the main barriers to commercial viability for ATMPs is the supply chain, which contributes significantly to the overall cost of goods ...

The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability...

How do you find the perfect CRO?

Matthew Durdy, Chief Business Officer at Cell & Gene Therapy Catapult, gives his perspective on the impact of Brexit on the UK's advanced...

DR Felicia Rosenthal, CEO, Cellgenix discusses raw material for cell and tissue-based products, GMP manufacturing considerations and scale-up...

What is risk? How can we accurately understand risk and apply this understanding to inform solutions for investors? There are no easy answers to...

As more and more approvals of immuno-oncology therapies become reality, how will these therapies be efficiently and sustainably scaled up and...

Dr Leeza Osipenko is Associate Director of NICE and works closely with EMA, MHRA, European HTA agencies and EUNETHTA. She chairs most of the...